Incyte's JAK inhibitor effective in PhII arthritis; dosing uncertainties remain
This article was originally published in Scrip
Executive Summary
Incyte has presented Phase II data for its JAK1 inhibitor INCB39110 in rheumatoid arthritis, adding to a growing body of evidence that the JAK class, used primarily in oncology also has potential in inflammation. However, the Incyte Phase II trial studied a relatively low two- or three-fold (depending on what is compared) dose range and it is not clear from the results presented so far that dosing has been precisely determined.